Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Eleanor Fleming, PhD, DDS, MPH, Julie Frantsve-Hawley, PhD, and Myechia Minter-Jordan, MD, MBA
Continued separation of dental and oral health from general medical care generates unnecessary prescriptions and pain management that are neither restorative nor responsive to patients’ primary complaints.
AMA J Ethics. 2022;24(1):E48-56. doi:
10.1001/amajethics.2022.48.